Librarian Capital's Research Library

Librarian Capital's Research Library

Share this post

Librarian Capital's Research Library
Librarian Capital's Research Library
Philip Morris: U.S. Ruling Against IQOS Has Little Impact (Preview)

Philip Morris: U.S. Ruling Against IQOS Has Little Impact (Preview)

Company Update (PM US) (Buy)

Librarian Capital's avatar
Librarian Capital
May 15, 2021
∙ Paid

Share this post

Librarian Capital's Research Library
Librarian Capital's Research Library
Philip Morris: U.S. Ruling Against IQOS Has Little Impact (Preview)
Share

Summary

  • We believe Friday's ITC ruling against IQOS, in the U.S. patent lawsuit brought by British American Tobacco, has limited impact.

  • We believe patent claims against IQOS have no merit; Philip Morris has already successfully invalidated several in other courts globally.

  • The ITC can ban U.S. imports of IQOS, but likely not immediately; existing IQOS sales in the U.S. are not material.

  • The whole lawsuit may become moot with ILUMA, a new device based on a different technology, is launched in H2 this year.

  • With shares at $97.70, we expect an exit price of $123 and a total return of 46% (12.0% annualized, including 5% in dividends) by 2024. Buy.

Introduction

On Friday (May 14), a U.S. judge released his "initial determination" on the U.S. International Trade Commission lawsuit filed by British American Tobacco (referred here as "BAT") against Philip Morris and Altria, finding that IQOS infringes two of BAT's patents.

We believe BAT's lawsuit has no merit and the ruling has little practical co…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Librarian Capital
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share